Hepcidin inhibition improves iron homeostasis in ferrous sulfate and LPS treatment model in mice

Abstract

Background Hepcidin, a liver-derived peptide, regulates the absorption, distribution, and circulation of iron in the body. Inflammation or iron overload stimulates hepcidin release, which causes the accumulation of iron in tissues. The inadequate levels of iron in circulation impair erythropoiesis. Inhibition of hepcidin may increase iron in circulation and improve efficient erythropoiesis. Activin-like kinase (ALK) inhibitors decrease hepcidin.

Methods In this work, we have investigated an ALK inhibitor LDN193189 for its efficacy in iron homeostasis. The effect of LDN193189 treatment was assessed in C57BL6/J mice, in which hepcidin was induced by either ferrous sulfate or lipopolysaccharide (LPS) injection.

Results After two hours of treatment, ferrous sulfate increased serum and liver iron, serum hepcidin, and liver hepcidin expression. On the other hand, LPS reduced serum iron in a dose-related manner after six hours of treatment. LDN193189 treatment increased serum iron, decreased spleen and liver iron, decreased serum hepcidin and liver hepcidin expression in ferrous sulfate-treated mice, and increased serum iron in LPS-induced hypoferremia. We observed that ferrous sulfate caused a significantly higher increase in liver iron, serum hepcidin, and liver hepcidin than turpentine oil or LPS in mice. Iron dextran (intraperitoneal or intravenous) increased serum iron, but LDN193189 did not show hyperferremia with iron dextran stimulus.

Conclusion Ferrous sulfate-induced hyperferremia can be a valuable and rapid screening model for assessing the efficacy of hepcidin inhibitors.

Key words

assessment - ferrous sulfate - hepcidin - LDN193189 - lipopolysaccharide

Publikationsverlauf

Eingereicht: 05. Juni 2021

Angenommen: 28. Juni 2021

Artikel online veröffentlicht:
26. Juli 2021

• References

• 1 Donovan A, Lima CA, Pinkus JL. et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 2005; 1: 191-200
• 2 Rodriguez R, Jung CL, Gabayan V. et al. Hepcidin induction by pathogens and pathogen-derived molecules is strongly dependent on interleukin-6. Infect Immun 2014; 82: 745-752
• 3 Rishi G, Wallace DF, Subramaniam VN. Hepcidin: regulation of the master iron regulator. Biosci Rep 2015; 35: e00192
• 4 Pantopoulos K. Inherited Disorders of Iron Overload. Front Nutr 2018; 5: 103
• 5 Ashby DR, Gale DP, Busbridge M. et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009; 75: 976-981
• 6 Cooke KS, Hinkle B, Salimi-Moosavi H. et al. A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. Blood 2013; 122: 3054-3061
• 7 National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. 8th ed. Washington (DC): National Academies Press (US); 2011
• 8 Katsarou A, Pantopoulos K. Hepcidin Therapeutics. Pharmaceuticals (Basel) 2018; 11: 127
• 9 Preza GC, Ruchala P, Pinon R. et al. Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload. J Clin Invest 2011; 121: 4880-4888
• 10 Liu J, Sun B, Yin H. et al. Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review. Medicine (Baltimore) 2016; 95: e3150
• 11 Tirnitz-Parker JE, Glanfield A, Olynyk JK. et al. Iron and hepatic carcinogenesis. Crit Rev Oncog 2013; 18: 391-407
• 12 Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta 2012; 1823: 1434-1443
• 13 Mayeur C, Kolodziej SA, Wang A. et al. Oral administration of a bone morphogenetic protein type I receptor inhibitor prevents the development of anemia of inflammation. Haematologica 2015; 100: e68-e71
• 14 van Santen S, de Mast Q, Oosting JD. et al. Hematologic parameters predicting a response to oral iron therapy in chronic inflammation. Haematologica 2014; 99: e171-e173
• 15 He H, Huang Q, Liu C. et al. Effectiveness of AOS–iron on iron deficiency anemia in rats. RSC advances 2019; 9: 5053-5063
• 16 Corradini E, Meynard D, Wu Q. et al. Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in mice. Hepatology 2011; 54: 273-284
• 17 Steinbicker AU, Sachidanandan C, Vonner AJ. et al. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood 2011; 117: 4915-4923
• 18 Yu PB, Hong CC, Sachidanandan C. et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 2008; 4: 33-41
• 19 Daba A, Gkouvatsos K, Sebastiani G. et al. Differences in activation of mouse hepcidin by dietary iron and parenterally administered iron dextran: compartmentalization is critical for iron sensing. J Mol Med (Berl) 2013; 91: 95-102
• 20 Langdon JM, Yates SC, Femnou LK. et al. Hepcidin-dependent and hepcidin-independent regulation of erythropoiesis in a mouse model of anemia of chronic inflammation. Am J Hematol 2014; 89: 470-479
• 21 Canali S, Core AB, Zumbrennen-Bullough KB. et al. Induces Noncanonical SMAD1/5/8 Signaling via BMP Type I Receptors in Hepatocytes: Evidence for a Role in Hepcidin Induction by Inflammation in Male Mice. Endocrinology 2016; 157: 1146-1162
• 22 Andriopoulos B, Corradini E, Xia Y. et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 2009; 41: 482-487
• 23 Salama MF, Bayele HK, Srai SS. Tumour necrosis factor alpha downregulates human hemojuvelin expression via a novel response element within its promoter. J Biomed Sci 2012; 19: 83